

## In the Claims

Please amend the claims as follows:

1. (Amended) A method of inducing ~~the~~ a body to produce an antibody against the region of the CCR5 receptor in wild type individuals, that [is affected by] interacts with the region that comprises the delta 32 deletion, said method comprising [using] administering a vaccine including a polypeptide having the following sequence:

Tyr-Ser-Gln-Tyr-Gln-Phe-Trp-Lys-Asn-Phe-Gln-Thr-Leu-  
LysIle-V al-Ile-Leu-Gly-Leu-V al-Leu-Pro-Leu-Leu-V al-  
Met-V al-Ile-Cys-TyrSer-Gly-Ile-Leu-Lys-Thr-Leu-Leu-Arg-  
Cys-Arg-Asn-Glu-Lys-Lys-Arg.

2. (Original) The method according to claim 1 wherein the vaccine is a derivative of said polypeptide.

3. (Amended) The method according to claim 1 wherein said vaccine produces an antibody with specificity for the CCR5 receptor [bound to the CCR5 site].

4. (Original) A method of treating a patient infected with HIV comprising using a vaccine including a polypeptide having the following sequence :

Tyr-Ser-Gln-Tyr-Gln-Phe-Trp-Lys-Asn-Phe-Gln-Thr-Leu-  
LysIle-Val-Ile-Leu-Gly-Leu-Val-Leu-Pro-Leu-Leu-Val-Met-  
Val-Ile-Cys-TyrSer-Gly-Ile-Leu-Lys-Thr-Leu-Leu-Arg-Cys-  
Arg-Asn-Glu-Lys-Lys-Arg

wherein said vaccine produces an antibody against the region of the CCR5 receptor in wild type individuals, that is affected by the delta 32 deletion.

5. (Original) The method according to claim 2 wherein the vaccine is a derivative of said polypeptide.

6. Withdrawn.

7. (Amended) A method of vaccination comprising administering a polypeptide to an individual, said [providing a] polypeptide [that causes] causing said individual [a body] to generate antibodies in response to said polypeptide, said antibodies [inactivating] inhibiting the activity of receptors through binding.

8. (Original) The method according to claim 7 wherein said polypeptide has the following sequence:

Tyr-Ser-Gln-Tyr-Gln-Phe-Trp-Lys-Asn-Phe-Gln-Thr-Leu-LysIle-Val-Ile-  
Leu-Gly-Leu-Val-Leu-Pro-Leu-Leu-Val-Met-Val-Ile-Cys-TyrSer-Gly-Ile-  
Leu-Lys-Thr-Leu-Leu-Arg-Cys-Arg-Asn-Glu-Lys-Lys-Arg.

9. (Original) The method according to claim 8 wherein the vaccine is a derivative of said polypeptide.

10. (Original) The method according to claim 9 wherein said vaccine produces an antibody bound to the CCR5 site.